Does spironolactone inhibit breast development in transgender women during the early phase of hormone therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Spironolactone Does Not Inhibit Breast Growth in Transgender Women

Based on the most recent and highest quality evidence, spironolactone does not inhibit breast development in transgender women during early hormone therapy. In fact, a 2024 randomized clinical trial directly comparing spironolactone to cyproterone acetate found no difference in breast development between the two antiandrogens 1.

Key Evidence from Direct Comparison

The 2024 randomized clinical trial by 1 specifically examined this question in 63 transgender women starting feminizing hormone therapy. After 6 months of treatment:

  • No difference in breast-chest distance between spironolactone 100mg daily and cyproterone acetate 12.5mg daily (mean difference 0.27 cm, 95% CI -0.82 to 1.35, p=0.6)
  • No difference in estimated breast volume between groups (mean difference 17.26 mL, 95% CI -16.94 to 51.47, p=0.3)
  • Both groups achieved similar breast development outcomes

This directly contradicts the concern that spironolactone might impair breast growth due to less potent androgen suppression.

Understanding the Conflicting Older Evidence

A 2012 retrospective study 2 found that previous spironolactone use was more common among transgender women requesting breast augmentation surgery (4.8% vs 1.8%, p=0.002). However, this study has significant limitations:

  • Retrospective design with inherent selection bias
  • Did not directly measure breast development
  • Confounded by self-medication patterns (which were also associated with augmentation requests)
  • Predates current standardized hormone protocols

The 2024 prospective randomized trial 1 provides much stronger evidence and should guide clinical practice.

Clinical Guidelines Support Spironolactone Use

Current transgender medicine guidelines 3 list spironolactone as one of the most popular adjunctive antiandrogen agents for feminizing hormone therapy, alongside cyproterone acetate and GnRH agonists. The 2023 Annual Review of Medicine 3 reports that:

  • Breast development was sustained during the first three years of gender-affirming hormone therapy
  • 1% of trans women had bra cup size less than A, 9% had A cup, 16% had B cup, and 1% had E cup
  • No mention of differential outcomes based on antiandrogen choice

Mechanism and Practical Considerations

Spironolactone works through:

  • Direct inhibition of testosterone secretion
  • Competitive inhibition of androgen receptor binding 4
  • Possible mild estrogenic activity 4

While cyproterone acetate more potently suppresses testosterone to <2 nmol/L (odds ratio 9.01, p=0.008) 1, this biochemical difference does not translate to clinically meaningful differences in breast development.

Clinical Recommendation Algorithm

For transgender women initiating feminizing hormone therapy:

  1. Choose antiandrogen based on:

    • Side effect profile (spironolactone: diuresis, hyperkalemia risk; cyproterone: mood effects, hepatotoxicity)
    • Patient preference and tolerability
    • Local availability and cost
    • NOT on concerns about breast development

  2. Monitor breast development over 2-3 years as this is the typical timeline 3

  3. If inadequate breast development occurs:

    • Optimize estradiol dosing (target premenopausal female range ~200 pg/mL) 4
    • Ensure testosterone suppression to female range (<50 ng/dL) 3
    • Consider switching antiandrogens if testosterone not adequately suppressed
    • Evaluate for other factors (genetics, body composition, adherence)

Important Caveats

  • Breast development is highly variable among all individuals regardless of antiandrogen choice 3
  • Genetics and individual response play major roles that cannot be predicted
  • Time is essential: breast development continues for 2-3 years and may extend beyond 3
  • The FDA label for spironolactone 5 notes feminization effects in male rat fetuses, but this relates to fetal development, not adult breast tissue response

Bottom line: Spironolactone is an appropriate antiandrogen choice for transgender women and should not be avoided due to concerns about breast development. The choice between antiandrogens should prioritize side effect profiles, patient preference, and practical considerations 1.

References

3
Guideline

update in adult transgender medicine.

Annual Review of Medicine, 2023

4
Guideline

endocrine treatment of transsexual persons: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2009

Related Questions

A patient who had leg cramps before initiating spironolactone now experiences persistent leg cramps while on spironolactone; what intervention should be taken?
What are the ingredients of the liquid formulation of spironolactone, and is it more palatable than the tablet?
How long does spironolactone take to lower blood pressure?
What is spironolactone used for in transgender women?
What is Aldacton (spironolactone), and what are the recommended starting dose, titration schedule, monitoring parameters, and contraindications for an adult patient without severe renal impairment?
What is the appropriate outpatient management for a 10-year-old child experiencing an asthma exacerbation?
How should I interpret a bone-specific alkaline phosphatase (bALP) test result?
What is a comprehensive inpatient cardiology care plan?
What is the appropriate itraconazole regimen and monitoring for treating seborrheic dermatitis in an adult patient without significant liver disease?
What is the appropriate management for a patient presenting with bilateral lower leg erythema and warmth, who has a history of peripheral vascular disease and diabetes mellitus?
What is the recommended dosing regimen for Florastor (Saccharomyces boulardii) in an adult patient taking antibiotics, including timing relative to the antibiotic doses and duration of therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.